VEGFR2/CD309 anticorps (AA 20-244)
Aperçu rapide pour VEGFR2/CD309 anticorps (AA 20-244) (ABIN5693262)
Antigène
Voir toutes VEGFR2/CD309 (VEGFR2) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 20-244
-
Fonction
- Anti-VEGF Receptor 2/Kdr Antibody
-
Réactivité croisée (Details)
- No cross-reactivity with other proteins.
-
Attributs du produit
- Anti-VEGF Receptor 2/Kdr Antibody (ABIN5693262). Tested in Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Mouse, Rat. This is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications.
-
Purification
- Immunogen affinity purified.
-
Immunogène
- E. coli-derived mouse VEGF Receptor 2 recombinant protein (Position: A20-L244).
-
Isotype
- IgG
-
-
-
-
Indications d'application
-
Western blot, 0.1-0.5 μg/mL
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL
Immunocytochemistry/Immunofluorescence, 2 μg/mL
Flow Cytometry (Fixed), 1-3 μg/1x106 cells
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
-
Concentration
- 500 μg/mL
-
Buffer
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg NaN3.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
-
Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
-
-
-
: "A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis." dans: Oncotarget, Vol. 7, Issue 36, pp. 57705-57713, (2018) (PubMed).
: "Effects of Chronic Exposure to Sodium Arsenite on Expressions of VEGF and VEGFR2 Proteins in the Epididymis of Rats." dans: BioMed research international, Vol. 2017, pp. 2597256, (2018) (PubMed).
: "Effects of propranolol and isoproterenol on infantile hemangioma endothelial cells in vitro." dans: Experimental and therapeutic medicine, Vol. 8, Issue 2, pp. 647-651, (2014) (PubMed).
: "Fructopyrano-(1?4)-glucopyranose inhibits the proliferation of liver cancer cells and angiogenesis in a VEGF/VEGFR dependent manner." dans: International journal of clinical and experimental medicine, Vol. 7, Issue 11, pp. 3859-69, (2014) (PubMed).
: "Role of transient receptor potential ion channels and evoked levels of neuropeptides in a formaldehyde-induced model of asthma in BALB/c mice." dans: PLoS ONE, Vol. 8, Issue 5, pp. e62827, (2013) (PubMed).
-
: "A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis." dans: Oncotarget, Vol. 7, Issue 36, pp. 57705-57713, (2018) (PubMed).
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Autre désignation
- Kdr
-
Sujet
-
Synonyms: Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase NYK, Protein-tyrosine kinase receptor flk-1, CD309, Kdr, Flk-1, Flk1
Tissue Specificity: Expressed in endothelial cells (at protein level). Detected in embryonic endothelial cells, as well as hematopoietic stem and progenitor cells. Detected in vascular endothelium. Expressed at high levels in adult heart, lung, kidney, brain and skeletal muscle, but is also expressed at lower levels in most other adult tissues.
Background: KDR (Kinase Insert Domain Receptor), also known as FLK1, VEGFR or VEGFR2, is a VEGF receptor. KDR is the human gene encoding it. Vascular endothelial growth factor (VEGF) is the only mitogen that specifically acts on endothelial cells. Its expression is upregulated by hypoxia, and its cell-surface receptor, known as fetal liver kinase-1 (Flk1) in mouse, is exclusively expressed in endothelial cells. Flk1 is the mouse homolog of KDR.
-
Poids moléculaire
- 150 kDa
-
ID gène
- 16542
-
UniProt
- P35918
-
Pathways
- Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
Antigène
-